Think of the inner circuitry of the brain as a traffic network. When nerve cells release a signal, the information speeds along various routes to its destination: another nerve cell elsewhere in the brain. Neurobiologist Josh Huang, PhD, is especially interested in a particular type of inhibitory nerve cells called chandelier cells.

The work of research team that includes Dr. David Montefiori of the Duke Human Vaccine Institute is highlighted in the NIH Director's Blog.

The human placenta performs a delicate balancing act: it must let beneficial nutrients pass from the mother to the developing fetus, but block harmful pathogens from making the same trip. Carolyn Coyne, PhD, investigates how the placenta has evolved to be such a fantastic protector but can also be vulnerable to pathogens.

When certain immune cells in our bodies are invaded by a dangerous pathogen, they sacrifice themselves to vanquish the intruders.

A new test can quickly test the ability of antibodies to neutralize spike proteins from different variants of COVID-19 simultaneously. The D4 assay shown here is the Teflon-like technology that makes the test possible.

When William J. Fulkerson, MD, MBA, steps down from his illustrious tenure as executive vice president of Duke University Health System (DUHS) at the end of this year, he will be celebrated as one of the most influential and successful figures in Duke Health’s 90-year history.

Emily Wang, MD’03, initially intended to study HIV research and treatment, but midway through medical school she became interested in the issues facing inmate populations. Now a professor in the Yale School of Medicine, she explores the health effects that mass incarceration has on populations both inside and outside of prison — a subject that the COVID-19 pandemic has thrown into sharp relief.

In a lot of ways, Susan Blackwell (Crawford), MHS, PA-C’89, and the physician assistant profession have grown up together. They were born at roughly the same time, matured in parallel and proximity, and for more than three decades they’ve been inextricably linked.

With $21 million in new funding from the NIAID, the network now includes eight centers in North America and will study adolescent lung transplant recipients as well as adult.

Nick Heaton, PhD, has turned his research focus from influenza to another RNA virus: COVID-19. He is using powerful gene-editing tools to identify candidates for host-directed therapeutics, which don’t attack the virus directly but instead target proteins the virus needs.